HOPA collects recent published article citations from peer-reviewed journals and makes that information available to our members. We invite you to take a look at the research our members have been conducting and involved with from the last 12 months.
If you would like to share your recent published research with other HOPA members use the Member Published Research form.
Published Research
Burris HA III, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi:10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. PMID: 29475723. (Submitted by John G. Kuhn, PharmD FCCP FHOPA)
Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi:10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26. PMID: 29074604. (Submitted by John G. Kuhn, PharmD FCCP FHOPA)
Clement JM, Holle LM. Safe administration of intra-cerebral spinal fluid (CSF) chemotherapy: time for guidelines. J Oncol Pract. 2017 Nov;13(11):713-718. http://ascopubs.org/doi/full/10.1200/JOP.2017.022038 (Submitted by Lisa M. Holle, PharmD BCOP FHOPA)
Dávila-González D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC. Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer. Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi:10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4. PMID: 29301832. (Submitted by John G. Kuhn, PharmD FCCP FHOPA)
Dey N, Williams C, Leyland-Jones B, De P. Mutation matters in precision medicine: a future to believe in. Cancer Treat Rev. 2017 Apr;55:136-149. doi:10.1016/j.ctrv.2017.03.002. Epub 2017 Mar. Review. PMID: 28371665. (Submitted by Casey Williams, PharmD BCOP FHOPA)
Dheeraj A, Rigby CM, O'Bryant CL, Agarwal C, Singh RP, Deep G, Agarwal R. Silibinin treatment inhibits the growth of hedgehog inhibitor-resistant basal cell carcinoma cells via targeting EGFR-MAPK-Akt and hedgehog signaling. Photochem Photobiol. 2017;93(4):999-1007. doi:10.1111/php.12727. (Submitted by Cindy L. O'Bryant, PharmD BCOP FCCP FHOPA)
El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF. Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 2018;81(4):659-670. doi:10.1007/s00280-018-3517-8. (Submitted by Cindy L. O'Bryant, PharmD BCOP FCCP FHOPA)
Frimpong JO, Tombleson R, Alsina M, Shapiro J, Kim J, Yue B, Perkins J, Nishihori T. Impact of obesity in patients with multiple myeloma receiving high-dose melphalan followed by autologous hematopoietic cell transplantation. Blood. 2016;128(22):4636. www.bloodjournal.org/content/128/22/4636 (Submitted by Justina Frimpong, PharmD BCOP)
Ganetsky A, Frey NV, Loren AW, Hexner EO, Mangan JK, Gill SI, Luger S, Cohen AD, Babushok DV, Stadtmauer EA, Smith J, Drobyski WR, Kraus SK, Timlin C, Porter DL. Tocilizumab is highly active for severe steroid-refractory acute graft-versus-host disease of the gastrointestinal tract. Blood. 2016;128(22):4636. www.bloodjournal.org/content/128/22/2245 (Submitted by Alex Ganetsky, PharmD BCOP)
Gatwood J, Gatwood KS, Gabre E, Alexander M. Impact of clinical pharmacists in outpatient oncology practices: a review. Am J Health Syst Pharm. 2017;74(19):1549-1557. doi:10.2146/ajhp160475. www.ajhp.org/content/74/19/1549.long?sso-checked=true (Submitted by Katie S. Gatwood, PharmD BCOP)
Gatwood KS, Culos KA, Binari LA, et al. Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic stem cell transplantation in severe aplastic anemia. Bone Marrow Transplant. 2018 Mar. doi:10.1038/s41409-018-0124-6. [Epub ahead of print]. https://www.nature.com/articles/s41409-018-0124-6 (Submitted by Katie S. Gatwood, PharmD BCOP)
Glode AE, Bodge M, Culver ME. Geriatric assessments and medication management in elderly oncology patients. Consult Pharm. 2017;Suppl B:1-20. doi:10.4140/TCP.s2017.001. (Submitted by Ashley E. Glode, PharmD BCOP)
Hanna KS. A review of immune checkpoint inhibitors for the management of locally advanced or metastatic urothelial carcinoma. Pharmacotherapy. 2017 Nov;37(11):1391-1405. doi:10.1002/phar.2033. https://onlinelibrary.wiley.com/doi/abs/10.1002/phar.2033 (Submitted by Kirollos S. Hanna, PharmD BCPS BCOP)
Hanna KS. The role of nutrition support in patients with cancer. PPP Mag. 2017 Nov;14(11):6. https://www.pppmag.com/article/2131 (Submitted by Kirollos S. Hanna, PharmD BCPS BCOP)
Hanna KS, Mancini R, Burtelow M, Bridges B. Aplastic anemia in a patient with anaplastic oligodendroglioma postradiation and concurrent temozolomide therapy: case report and review of the literature. J Hematol Oncol Pharm. 2018 Mar;8(1). http://jhoponline.com/jhop-issue-archive/2018-issues/jhop-march-2018-vol-8-no-1/17378-aplastic-anemia-in-a-patient-with-anaplastic-oligodendroglioma-postradiation-and-concurrent-temozolomide-therapy-case-report-and-review-of-the-literature (Submitted by Kirollos S. Hanna, PharmD BCPS BCOP)
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018 Apr 1;29(4):872-880. doi:10.1093/annonc/mdy025. PMID: 29360925. (Submitted by Casey Williams, PharmD BCOP FHOPA)
Hogue S, Ineck J, Mancini R. Evaluation of the duration of oral chemotherapies use at a community cancer center. J Hematol Oncol Pharm. 2017;7(4):134-138. http://jhoponline.com/jhop-issue-archive/2017-issues/jhop-december-2017-vol-7-no-4/17335-evaluation-of-the-duration-of-oral-chemotherapies-use-at-a-community-cancer-center (Submitted by Sarah Hogue, PharmD)
Holle LH, Liu J. Tisagnelecleucel (Kymriah) for acute lymphoblastic leukemia. Drug Topics. 2017 Nov. www.drugtopics.com/clinical-news/tisagenlecleucel-kymriah-acute-lymphoblastic-leukemia (Submitted by Lisa M. Holle, PharmD BCOP FHOPA)
Johnson EJ, Gonzalez-Perez V, Tian DD, Lin YS, Unadkat JD, Rettie AE, Shen DD, McCune JS, Paine MF. Selection of priority natural products for evaluation as potential precipitants of natural product-drug interactions: a NaPDI center recommended approach. Drug Metab Dispos. 2018 May:pii:dmd.118.081273. doi:10.1124/dmd.118.081273. [Epub ahead of print]. PMID: 29735752 (Submitted by Jeannine S. McCune)
Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I study of Enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. Mol Cancer Ther. 2018;17(1):215-221. doi:10.1158/1535-7163.MCT-17-0330. (Submitted by Cindy L. O'Bryant, PharmD BCOP FCCP FHOPA)
Lay JO Jr, Korfmacher WA, Miller DW, Siitonen P, Holder CL, Gosnell AB. Desorption chemical ionization and fast atom bombardment mass spectrometric studies of the glucuronide metabolites of doxylamine. Biomed Environ Mass Spectrom. 1986 Nov;13(11):627-32. PMID: 2948588. (Submitted by John G. Kuhn, PharmD, FCCP FHOPA)
Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. J Clin Oncol. 2017 Oct 2:JCO2017744102. doi:10.1200/JCO.2017.74.4102. [Epub ahead of print]. PMID: 28968172. (Submitted by R. Donald Harvey, PharmD BCOP FCCP FHOPA)
Lubcke N, Van Camp K. Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma. J Oncol Pharm Pract. 2018 Jan:1078155217752537. doi:10.1177/1078155217752537. (Submitted by Nicole Lubcke, PharmD BCOP)
Lucas AJ, Olin JL, Coleman MD. Management and preventive measures for febrile neutropenia. P T. 2018 Apr;43(4):228-232. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871243/ (Submitted by Jacqueline L. Olin)
Ly AC, Olin JL, Smith MB. Alectinib for advanced ALK-positive non-small-cell lung cancer. Am J Health Syst Pharm. 2018 Apr;75(8):515-522. www.ajhp.org/content/75/8/515.long?sso-checked=true (Submitted by Jacqueline L Olin)
Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Harvey RD, Schilsky RL. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018 Feb 14:JCO2017774893. doi:10.1200/JCO.2017.77.4893.[Epub ahead of print]. PMID: 29443651. (Submitted by R. Donald Harvey, PharmD BCOP FCCP FHOPA)
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med. 2018;378(21):2036-2044. doi:10.1056/NEJMhle1800125. PMID: 29791832. (Submitted by R. Donald Harvey, PharmD BCOP FCCP FHOPA)
Maples KT, Sabo RT, McCarty JM, Toor AA, Hawks KG. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leuk Lymphoma. 2018 Apr(4);1-6. doi:10.1080/10428194.2018.1443334. [EPub ahead of print]. https://www.tandfonline.com/eprint/8iEZW4wassi6daNdvxPs/full (Submitted by Kelly G. Hawks, PharmD BCOP, and Kathryn Maples, PharmD)
Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy. 2018 Mar;38(3):357-369. doi:10.1002/phar.2076. Epub 2018 Feb. (Submitted by Karen M. Fancher, PharmD BCOP)
Martin GA, Chen AH, Parikh K. A novel use of olaparib for the treatment of metastatic castration-recurrent prostate cancer. Pharmacotherapy. 2017 Nov;37(11):1406-1414. https://onlinelibrary.wiley.com/doi/abs/10.1002/phar.2027 (Submitted by Grace A. Martin, PharmD)
McCune JS, Storer B, Thomas S, McKiernan J, Gupta R, Sandmaier BM. Inosine monophosphate dehydrogenase pharmacogenetics in hematopoietic cell transplantation patients. Biol Blood Marrow Transplant. 2018 Apr:pii:S1083-8791(18)30187-3. doi:10.1016/j.bbmt.2018.04.006. [Epub ahead of print]. PMID: 29656138. (Submitted by Jeannine S. McCune)
McDonald M, Culos KA, Gatwood KS, et al. Defining incidence and risk factors for catheter-associated bloodstream infections in an outpatient adult hematopoietic cell transplantation program. Biol Blood Marrow Transplant. 2018 May 9. pii: S1083-8791(18)30253-2. doi:10.1016/j.bbmt.2018.04.031. https://www.bbmt.org/article/S1083-8791(18)30253-2/fulltext (Submitted by Katie S. Gatwood, PharmD BCOP)
Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018 Jan;136(1):79-86. doi:10.1007/s11060-017-2624-4. Epub 2017 Oct 7. PMID: 28988377. (Submitted by John G. Kuhn, PharmD FCCP FHOPA)
Olin JL, Griffiths CL, Smith MB. Venetoclax: a novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies. J Oncol Pharm Pract. 2017 Jan 1:1078155217718383. doi:10.1177/1078155217718383. http://journals.sagepub.com/doi/pdf/10.1177/1078155217718383 (Submitted by Jacqueline L. Olin)
Paine MF, Shen DD, McCune JS. Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI center commentary. Drug Metab Dispos. 2018 May:pii:dmd.117.079962. doi:10.1124/dmd.117.079962. [Epub ahead of print]. PMID: 29735755 (Submitted by Jeannine S. McCune)
Pritchard ER, Waddell JA, Crane BJ, Porter A, Roberts S, Thomas AT, Yates D. Microbial growth of single-dose antineoplastic drug vials at 28 days. JHOP. 2018;8(1). http://jhoponline.com/jhop-issue-archive/2018-issues/jhop-march-2018-vol-8-no-1/17375-microbial-growth-of-single-dose-antineoplastic-drug-vials-at-28-days (Submitted by Elizabeth Ryan Pritchard, PharmD BCOP)
Puri S, Holle LM, Forouhar FA, Clement JA. Subcutaneous metastasis from recurrent basaxoid squamous cell carcinoma of the esophagus. J Oncol Pharm Pract. 2017 Jan 1:1078155217736920. doi:10.1177/1078155217736920. [Epub ahead of print] https://doi.org/10.1177/1078155217736920 (Submitted by Lisa M. Holle, PharmD BCOP FHOPA)
Schultz TE, Lynch AC. Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase. J Oncol Pharm Pract. 2018 Jan 1:1078155218769126. [Epub ahead of print]. (Submitted by Thomas Schultz, PharmD)
Signorelli J, Gandhi A. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: a pilot study. Journal Oncol Pharm Pract. 2017 Jan 1:1078155217739683. doi:10.1177/1078155217739683. [Epub ahead of print]. http://journals.sagepub.com/doi/abs/10.1177/1078155217739683?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& (Submitted by Jessie Signorelli, PharmD)
Tollkuci, E. Isavuconazole therapy in a FLT3 mutated acute myeloid leukemia patient receiving midostaurin: a case report. J Oncol Pharm Pract. 2018 Jan 1:1078155218764257. doi:10.1177/1078155218764257. http://journals.sagepub.com/doi/pdf/10.1177/1078155218764257 (Submitted by Eris Tollkuci, PharmD BCOP)
Trepte ML, Auten JJ, Clark SM, van Deventer HW. Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. J Oncol Pharm Pract. 2018 Jan 1:1078155218758499. doi:10.1177/1078155218758499. (Submitted by Stephen M. Clark, PharmD BCOP)
Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Yang JC, Bui K, Weilert D, Harvey RD. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018 Jan 30. doi:10.1111/bcp.13534. [Epub ahead of print]. PMID: 29381826. (Submitted by R. Donald Harvey, PharmD BCOP FCCP FHOPA)
Xu B, Krie A, De P, Williams C, Elsey R, Klein J, Leyland-Jones B. Utilizing tumor and plasma liquid biopsy in treatment decision making for an estrogen receptor-positive advanced breast cancer patient. Cureus. 2017 Jun 29;9(6):e1408. doi:10.7759/cureus.1408. PMID: 28856074. (Submitted by Casey Williams, PharmD BCOP FHOPA)
Zanotto-Filho A, Rajamanickam S, Loranc E, Masamsetti VP, Gorthi A, Romero JC, Tonapi S, Gonçalves RM, Reddick RL, Benavides R, Kuhn J, Chen Y, Bishop AJR. Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Lett. 2018 Jul 1;425:101-115. doi:10.1016/j.canlet.2018.03.037. Epub 2018 Mar 30. PMID: 29608984. (Submitted by John G. Kuhn, PharmD FCCP FHOPA)
Submit Your Own Published Research
If you have published anything within the last 12 months that you would be willing to share as an available resource to other members, please click the link to below to access the form for submitting your citation(s).
Example:
Fizazi K, Tran NP, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.